Isoform-selective HSP90 inhibition as a precision therapeutic strategy for neurodegenerative and metabolic diseases.
- DOI
- 10.1016/j.pnpbp.2026.111834
- Published
- 2026 Aug 30
- Container
- Progress in neuro-psychopharmacology & biological psychiatry
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.pnpbp.2026.111834,
title = {Isoform-selective HSP90 inhibition as a precision therapeutic strategy for neurodegenerative and metabolic diseases.},
author = {Alanazi SM and Al-Kuraishy HM and Alexiou A and Papadakis M and Faheem SA and Batiha GE},
year = {2026},
journal = {Progress in neuro-psychopharmacology \& biological psychiatry},
doi = {10.1016/j.pnpbp.2026.111834},
url = {https://doi.org/10.1016/j.pnpbp.2026.111834}
}RIS
TY - JOUR TI - Isoform-selective HSP90 inhibition as a precision therapeutic strategy for neurodegenerative and metabolic diseases. AU - Alanazi SM AU - Al-Kuraishy HM AU - Alexiou A AU - Papadakis M AU - Faheem SA AU - Batiha GE PY - 2026 JO - Progress in neuro-psychopharmacology & biological psychiatry DO - 10.1016/j.pnpbp.2026.111834 UR - https://doi.org/10.1016/j.pnpbp.2026.111834 ER -
APA
SM, A., HM, A., A, A., M, P., SA, F., & GE, B. (2026). Isoform-selective HSP90 inhibition as a precision therapeutic strategy for neurodegenerative and metabolic diseases.. Progress in neuro-psychopharmacology & biological psychiatry. https://doi.org/10.1016/j.pnpbp.2026.111834
Source records
- pubmed · retrieved 2026-09-26T23:38:28.027Z